The stock will trade on the CY2027 guidance narrative and FDA decision on the second-generation LungFit PH PMA supplement. Monitor the FDA timeline and any updates on the reverse stock split to regain Nasdaq compliance. The $18.2M ELOC introduces potential dilution risk if drawn.
Price Chart
Executive Summary
Beyond Air reported fiscal Q4 and full-year 2026 results with revenue up 107% YoY to $7.7M, but net loss widened to $33.2M. The company issued CY2026 revenue guidance of $8M (15% growth) and CY2027 guidance of $16-18M (110% growth) contingent on FDA approval of the second-generation LungFit PH system. The fiscal year-end is being changed from March 31 to December 31, effective December 31, 2026.
Key Financial Metrics
Key Facts
- FY2026 revenue $7.7M (+107% YoY); Q4 revenue $1.9M (+66% YoY)
- Net loss attributable to common stockholders FY2026: ($33.2M) or ($4.01)/share; Q4: ($10.3M) or ($0.77)/share
- Cash, cash equivalents, restricted cash and marketable securities of $17.3M as of March 31, 2026
- Long-term debt $21.6M; $18.2M available under equity line of credit
- Revenue guidance: $8M for CY2026 (~15% growth); $16-18M for CY2027 (>110% growth)
- Fiscal year-end changed from March 31 to December 31, effective December 31, 2026
- Nasdaq granted continued listing subject to regaining bid price compliance by July 31, 2026; 1-for-20 reverse stock split approved
Financial Impact
Revenue growth of 107% to $7.7M in FY2026, but net loss of $33.2M and cash burn of $19.1M; guidance implies significant acceleration in CY2027 if FDA approval is obtained
Risk Factors
- FDA approval of second-generation LungFit PH is uncertain and critical to CY2027 guidance
- Cash runway limited to calendar 2027; additional capital likely needed
- Nasdaq delisting risk if bid price compliance not regained by July 31, 2026
- High debt load ($21.6M) and ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030305 |
| Document: form8-k.htm | 0001493152-26-030305 |
| Document: 0001493152-26-030305-index-headers.html | 0001493152-26-030305 |
| Document: 0001493152-26-030305-index.html | 0001493152-26-030305 |
| Document: 0001493152-26-030305.txt | 0001493152-26-030305 |
| 8-K Data (Synthetic) | 0001493152-26-030305 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | SC 13G/A | $2.34 | awaiting T+60 | — | $2.24 (−4.27%) |
Oct 8, 2026 18d ago | 8-K | $2.31 | awaiting T+60 | — | $2.24 (−3.03%) |
Sep 24, 2026 4w ago | 8-K | $2.85 | awaiting T+60 | — | $2.24 (−21.40%) |
Aug 25, 2026 8w ago | EFFECT | $4.98 | awaiting T+60 | — | $2.24 (+55.02%) |
Jul 31, 2026 12w ago | Insider Cluster | $6.33 | awaiting T+60 | — | $2.24 (−64.61%) |
Jul 31, 2026 12w ago | 8-K | $5.28 | awaiting T+60 | — | $2.24 (+57.54%) |
Jul 2, 2026 16w ago | Court Ruling | $0.4390 $0.1415 | ▲ +67.77% | ▲ +69.49% | $2.24 (−410.25%) |
Jun 26, 2026 17w ago | 8-K | $0.4646 $0.1505 | ▼ −67.61% | ▼ −71.22% | $2.24 (+382.14%) |
Jun 22, 2026 17w ago | 8-K | $0.4680 $0.1540 | ▼ −67.09% | ▼ −71.05% | $2.24 (+378.63%) |
Apr 20, 2026 27w ago | Press Release | $10.90 $5.55 | ▼ −49.08% | ▼ −55.28% | $2.24 (−79.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers